HoraceQ personal page - To The Moon

HoraceQ

HoraceQ

No personal profile

3Follow

0Followers

0Topic

0Badge

2021-07-22

Like

4 Biotech Stocks That Could Be Bargains

2021-07-20

Like

Sorry, the original content has been removed

2021-07-11

Any security issue? ?

Sorry, the original content has been removed

2021-07-06

Nice

OIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal

2021-06-25

Good stock

2021-06-25

Good?

Sorry, the original content has been removed

2021-06-25

Pls like and share

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4087701495835990","uuid":"4087701495835990","gmtCreate":1624600287891,"gmtModify":1624606314312,"name":"HoraceQ","pinyin":"horaceq","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.07","exceedPercentage":"60.92%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":172104650,"gmtCreate":1626941945570,"gmtModify":1703480991204,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172104650","repostId":"1197792637","repostType":4,"repost":{"id":"1197792637","kind":"news","pubTimestamp":1626941717,"share":"https://ttm.financial/m/news/1197792637?lang=&edition=fundamental","pubTime":"2021-07-22 16:15","market":"us","language":"en","title":"4 Biotech Stocks That Could Be Bargains","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792637","media":"Barron's","summary":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnol","content":"<p>Biotech stocks have had an uneven 2021 so far.</p>\n<p>One major biotech fund, the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b>, which focuses on the bigger biotech players, is up 9%, just behind the&nbsp;S&amp;P 500 index,which is up 14.3%. Another important fund, the<b>&nbsp;<a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b>, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.</p>\n<p>The success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.</p>\n<p>Picking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.</p>\n<p>For those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.</p>\n<h3><b>4 Undervalued Biotech Stocks</b></h3>\n<p>These are the four biotech stocks in the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b> and the <b><a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b> with market values over $5 billion that trade the farthest below their average analyst price targets.</p>\n<table>\n <thead>\n  <tr>\n   <th>Company / Ticker</th>\n   <th>Recent Price</th>\n   <th>Average Target Price</th>\n   <th>Implied Gain</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>TG Therapeutics / TGTX</td>\n   <td>$37.32</td>\n   <td>$75.88</td>\n   <td>103.3%</td>\n  </tr>\n  <tr>\n   <td>Vir Biotechnology / VIR</td>\n   <td>$37.91</td>\n   <td>$74.29</td>\n   <td>96.0%</td>\n  </tr>\n  <tr>\n   <td>Ultragenyx Pharmaceutical / RARE</td>\n   <td>$85.49</td>\n   <td>$153.12</td>\n   <td>79.1%</td>\n  </tr>\n  <tr>\n   <td>Exelixis / EXEL</td>\n   <td>$16.67</td>\n   <td>$29.54</td>\n   <td>77.2%</td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: FactSet</i></p>\n<p>Analysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we&nbsp;looked at the five health-care stocks in the S&amp;P 500 that trade the farthest below their average analyst&nbsp;price&nbsp;targets.</p>\n<p>This time, we’ve looked at the stocks in the SPDR S&amp;P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.</p>\n<p>We set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.</p>\n<p>The stocks that passed the screen are&nbsp;<b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a></b>, and<b>&nbsp;<a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.</p>\n<p>The stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.</p>\n<p><b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b> stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.</p>\n<p>Analysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.</p>\n<p>The average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.</p>\n<p>Another stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy&nbsp;jointly developed by Vir and&nbsp;<b><a href=\"https://laohu8.com/S/GSK\">GlaxoSmithKline PLC</a></b> to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.</p>\n<p>Vir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.</p>\n<p>Of the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.</p>\n<p>Also on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.</p>\n<p>The company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.</p>\n<p>“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.</p>\n<p>The average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.</p>\n<p>The final stock to pass our screen was <b><a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.</p>\n<p>The average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks That Could Be Bargains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks That Could Be Bargains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which ...</p>\n\n<a href=\"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","VIR":"Vir Biotechnology, Inc.","XBI":"SPDR S&P Biotech ETF","RARE":"Ultragenyx Pharmaceutical Inc","IBB":"生物科技指数ETF-iShares Nasdaq","TGTX":"TG Therapeutics Inc.","EXEL":"伊克力西斯"},"source_url":"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197792637","content_text":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which is up 14.3%. Another important fund, the Spdr S&P Biotech Etf, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.\nThe success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.\nPicking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.\nFor those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.\n4 Undervalued Biotech Stocks\nThese are the four biotech stocks in the iShares Nasdaq Biotechnology ETF and the Spdr S&P Biotech Etf with market values over $5 billion that trade the farthest below their average analyst price targets.\n\n\n\nCompany / Ticker\nRecent Price\nAverage Target Price\nImplied Gain\n\n\n\n\nTG Therapeutics / TGTX\n$37.32\n$75.88\n103.3%\n\n\nVir Biotechnology / VIR\n$37.91\n$74.29\n96.0%\n\n\nUltragenyx Pharmaceutical / RARE\n$85.49\n$153.12\n79.1%\n\n\nExelixis / EXEL\n$16.67\n$29.54\n77.2%\n\n\n\nSource: FactSet\nAnalysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we looked at the five health-care stocks in the S&P 500 that trade the farthest below their average analyst price targets.\nThis time, we’ve looked at the stocks in the SPDR S&P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.\nWe set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.\nThe stocks that passed the screen are TG Therapeutics, Vir Biotechnology, Inc., Ultragenyx Pharmaceutical, and Exelixis, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.\nThe stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.\nTG Therapeutics stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.\nAnalysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.\nThe average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.\nAnother stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy jointly developed by Vir and GlaxoSmithKline PLC to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.\nVir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.\nOf the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.\nAlso on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.\nThe company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.\n“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.\nThe average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.\nThe final stock to pass our screen was Exelixis, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.\nThe average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178119802,"gmtCreate":1626791306306,"gmtModify":1703765317810,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178119802","repostId":"1199016731","repostType":4,"isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148612802,"gmtCreate":1625971047206,"gmtModify":1703751415913,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Any security issue? ?","listText":"Any security issue? ?","text":"Any security issue? ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/148612802","repostId":"1184476863","repostType":4,"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154789947,"gmtCreate":1625545497989,"gmtModify":1703743433788,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154789947","repostId":"1190430616","repostType":4,"repost":{"id":"1190430616","kind":"news","pubTimestamp":1625528334,"share":"https://ttm.financial/m/news/1190430616?lang=&edition=fundamental","pubTime":"2021-07-06 07:38","market":"us","language":"en","title":"OIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1190430616","media":"CNBC","summary":"Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil","content":"<div>\n<p>Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil-producing allies werepostponed indefinitely, with the group failing to reach an agreement on ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil-producing allies werepostponed indefinitely, with the group failing to reach an agreement on ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1190430616","content_text":"Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil-producing allies werepostponed indefinitely, with the group failing to reach an agreement on production policy for August and beyond.\nWest Texas Intermediate crude futures, the U.S. oil benchmark, advanced 1.56%, or $1.17, to $76.33 per barrel, its highest level since October 2018. International benchmarkBrent cruderose 1.2%, or 93 cents, to $77.10 per barrel.\nDiscussions beganlast weekbetween OPEC and its allies, known as OPEC+, as the energy alliance sought to establish output policy for the remainder of the year. The group on Friday voted on a proposal that would have returned 400,000 barrels per day to the market each month from August through December, resulting in an additional 2 million barrels per day by the end of the year. Members also proposed extending the output cuts through the end of 2022.\nThe United Arab Emirates rejected these proposals, however, and talks stretched from Thursday to Friday as the group tried to reach a consensus. Initially, discussions were set to resume on Monday but were ultimately called off.\n“The date of the next meeting will be decided in due course,” OPEC Secretary General Mohammad Barkindo said in a statement.\nOPEC+ took historic measures in April 2020 and removed nearly 10 million barrels per day of production in an effort to support prices as demand for petroleum-products plummeted. Since then, the group has been slowly returning barrels to the market, while meeting on a near monthly basis to discuss output policy.\n“For us, it wasn’t a good deal,” UAE Minister of Energy and Infrastructure Suhail Al Mazroueitold CNBC on Sunday. He added that the country would support a short-term increase in supply, but wants better terms if the policy is to be extended through 2022.\nOil’s blistering rally this year — WTI has gained 57% during 2021 — meant that ahead of last week’s meeting many Wall Street analysts expected the group to boost production in an effort to curb the spike in prices.\n“With no increase in production, the forthcoming growth in demand should see global energy markets tighten up at an even faster pace than anticipated,” analysts at TD Securities wrote in a note to clients.\n“This impasse will lead to a temporary and significantly larger-than-anticipated deficit, which should fuel even higher prices for the time being. The summer breakout in oil prices is set to gather steam at a fast clip,” the firm added.\n— CNBC’s Sam Meredith contributed reporting.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122183719,"gmtCreate":1624604037331,"gmtModify":1703841523325,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Good stock","listText":"Good stock","text":"Good stock","images":[{"img":"https://static.tigerbbs.com/4f8385126ac4e0cf0ec5814a4a5cadee","width":"1080","height":"2110"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122183719","isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":122189388,"gmtCreate":1624603925044,"gmtModify":1703841520236,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Good?&nbsp;","listText":"Good?&nbsp;","text":"Good?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122189388","repostId":"1114781833","repostType":4,"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122180356,"gmtCreate":1624603829075,"gmtModify":1703841518779,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Pls like and share","listText":"Pls like and share","text":"Pls like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122180356","repostId":"1142508463","repostType":4,"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":178119802,"gmtCreate":1626791306306,"gmtModify":1703765317810,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178119802","repostId":"1199016731","repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://ttm.financial/m/news/1199016731?lang=&edition=fundamental","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":"<blockquote>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n</blockquote>\n<p>(July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.</p>\n<p><img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"></p>\n<p><b>So what</b></p>\n<p>The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According to<i>New York Times</i>data, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.</p>\n<p>So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(<b>Pfizer</b>) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.</p>\n<p><b>Now what</b></p>\n<p>If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.</p>\n<p>Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","AZN":"阿斯利康","MRNA":"Moderna, Inc.","CVAC":"CureVac B.V.","SNY":"赛诺菲安万特","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东","BNTX":"BioNTech SE","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154789947,"gmtCreate":1625545497989,"gmtModify":1703743433788,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154789947","repostId":"1190430616","repostType":4,"repost":{"id":"1190430616","kind":"news","pubTimestamp":1625528334,"share":"https://ttm.financial/m/news/1190430616?lang=&edition=fundamental","pubTime":"2021-07-06 07:38","market":"us","language":"en","title":"OIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1190430616","media":"CNBC","summary":"Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil","content":"<div>\n<p>Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil-producing allies werepostponed indefinitely, with the group failing to reach an agreement on ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOIL AND GAS Oil prices jump to multiyear highs after OPEC+ talks yield no production deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil-producing allies werepostponed indefinitely, with the group failing to reach an agreement on ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/07/05/oil-prices-jump-to-multiyear-highs-after-opec-talks-yield-no-production-deal-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1190430616","content_text":"Oil jumped to its highest level in nearly three years on Monday after talks between OPEC and its oil-producing allies werepostponed indefinitely, with the group failing to reach an agreement on production policy for August and beyond.\nWest Texas Intermediate crude futures, the U.S. oil benchmark, advanced 1.56%, or $1.17, to $76.33 per barrel, its highest level since October 2018. International benchmarkBrent cruderose 1.2%, or 93 cents, to $77.10 per barrel.\nDiscussions beganlast weekbetween OPEC and its allies, known as OPEC+, as the energy alliance sought to establish output policy for the remainder of the year. The group on Friday voted on a proposal that would have returned 400,000 barrels per day to the market each month from August through December, resulting in an additional 2 million barrels per day by the end of the year. Members also proposed extending the output cuts through the end of 2022.\nThe United Arab Emirates rejected these proposals, however, and talks stretched from Thursday to Friday as the group tried to reach a consensus. Initially, discussions were set to resume on Monday but were ultimately called off.\n“The date of the next meeting will be decided in due course,” OPEC Secretary General Mohammad Barkindo said in a statement.\nOPEC+ took historic measures in April 2020 and removed nearly 10 million barrels per day of production in an effort to support prices as demand for petroleum-products plummeted. Since then, the group has been slowly returning barrels to the market, while meeting on a near monthly basis to discuss output policy.\n“For us, it wasn’t a good deal,” UAE Minister of Energy and Infrastructure Suhail Al Mazroueitold CNBC on Sunday. He added that the country would support a short-term increase in supply, but wants better terms if the policy is to be extended through 2022.\nOil’s blistering rally this year — WTI has gained 57% during 2021 — meant that ahead of last week’s meeting many Wall Street analysts expected the group to boost production in an effort to curb the spike in prices.\n“With no increase in production, the forthcoming growth in demand should see global energy markets tighten up at an even faster pace than anticipated,” analysts at TD Securities wrote in a note to clients.\n“This impasse will lead to a temporary and significantly larger-than-anticipated deficit, which should fuel even higher prices for the time being. The summer breakout in oil prices is set to gather steam at a fast clip,” the firm added.\n— CNBC’s Sam Meredith contributed reporting.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172104650,"gmtCreate":1626941945570,"gmtModify":1703480991204,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172104650","repostId":"1197792637","repostType":4,"repost":{"id":"1197792637","kind":"news","pubTimestamp":1626941717,"share":"https://ttm.financial/m/news/1197792637?lang=&edition=fundamental","pubTime":"2021-07-22 16:15","market":"us","language":"en","title":"4 Biotech Stocks That Could Be Bargains","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792637","media":"Barron's","summary":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnol","content":"<p>Biotech stocks have had an uneven 2021 so far.</p>\n<p>One major biotech fund, the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b>, which focuses on the bigger biotech players, is up 9%, just behind the&nbsp;S&amp;P 500 index,which is up 14.3%. Another important fund, the<b>&nbsp;<a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b>, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.</p>\n<p>The success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.</p>\n<p>Picking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.</p>\n<p>For those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.</p>\n<h3><b>4 Undervalued Biotech Stocks</b></h3>\n<p>These are the four biotech stocks in the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b> and the <b><a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b> with market values over $5 billion that trade the farthest below their average analyst price targets.</p>\n<table>\n <thead>\n  <tr>\n   <th>Company / Ticker</th>\n   <th>Recent Price</th>\n   <th>Average Target Price</th>\n   <th>Implied Gain</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>TG Therapeutics / TGTX</td>\n   <td>$37.32</td>\n   <td>$75.88</td>\n   <td>103.3%</td>\n  </tr>\n  <tr>\n   <td>Vir Biotechnology / VIR</td>\n   <td>$37.91</td>\n   <td>$74.29</td>\n   <td>96.0%</td>\n  </tr>\n  <tr>\n   <td>Ultragenyx Pharmaceutical / RARE</td>\n   <td>$85.49</td>\n   <td>$153.12</td>\n   <td>79.1%</td>\n  </tr>\n  <tr>\n   <td>Exelixis / EXEL</td>\n   <td>$16.67</td>\n   <td>$29.54</td>\n   <td>77.2%</td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: FactSet</i></p>\n<p>Analysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we&nbsp;looked at the five health-care stocks in the S&amp;P 500 that trade the farthest below their average analyst&nbsp;price&nbsp;targets.</p>\n<p>This time, we’ve looked at the stocks in the SPDR S&amp;P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.</p>\n<p>We set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.</p>\n<p>The stocks that passed the screen are&nbsp;<b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a></b>, and<b>&nbsp;<a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.</p>\n<p>The stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.</p>\n<p><b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b> stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.</p>\n<p>Analysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.</p>\n<p>The average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.</p>\n<p>Another stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy&nbsp;jointly developed by Vir and&nbsp;<b><a href=\"https://laohu8.com/S/GSK\">GlaxoSmithKline PLC</a></b> to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.</p>\n<p>Vir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.</p>\n<p>Of the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.</p>\n<p>Also on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.</p>\n<p>The company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.</p>\n<p>“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.</p>\n<p>The average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.</p>\n<p>The final stock to pass our screen was <b><a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.</p>\n<p>The average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks That Could Be Bargains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks That Could Be Bargains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which ...</p>\n\n<a href=\"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","VIR":"Vir Biotechnology, Inc.","XBI":"SPDR S&P Biotech ETF","RARE":"Ultragenyx Pharmaceutical Inc","IBB":"生物科技指数ETF-iShares Nasdaq","TGTX":"TG Therapeutics Inc.","EXEL":"伊克力西斯"},"source_url":"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197792637","content_text":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which is up 14.3%. Another important fund, the Spdr S&P Biotech Etf, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.\nThe success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.\nPicking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.\nFor those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.\n4 Undervalued Biotech Stocks\nThese are the four biotech stocks in the iShares Nasdaq Biotechnology ETF and the Spdr S&P Biotech Etf with market values over $5 billion that trade the farthest below their average analyst price targets.\n\n\n\nCompany / Ticker\nRecent Price\nAverage Target Price\nImplied Gain\n\n\n\n\nTG Therapeutics / TGTX\n$37.32\n$75.88\n103.3%\n\n\nVir Biotechnology / VIR\n$37.91\n$74.29\n96.0%\n\n\nUltragenyx Pharmaceutical / RARE\n$85.49\n$153.12\n79.1%\n\n\nExelixis / EXEL\n$16.67\n$29.54\n77.2%\n\n\n\nSource: FactSet\nAnalysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we looked at the five health-care stocks in the S&P 500 that trade the farthest below their average analyst price targets.\nThis time, we’ve looked at the stocks in the SPDR S&P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.\nWe set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.\nThe stocks that passed the screen are TG Therapeutics, Vir Biotechnology, Inc., Ultragenyx Pharmaceutical, and Exelixis, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.\nThe stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.\nTG Therapeutics stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.\nAnalysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.\nThe average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.\nAnother stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy jointly developed by Vir and GlaxoSmithKline PLC to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.\nVir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.\nOf the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.\nAlso on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.\nThe company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.\n“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.\nThe average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.\nThe final stock to pass our screen was Exelixis, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.\nThe average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122180356,"gmtCreate":1624603829075,"gmtModify":1703841518779,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Pls like and share","listText":"Pls like and share","text":"Pls like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122180356","repostId":"1142508463","repostType":4,"repost":{"id":"1142508463","kind":"news","pubTimestamp":1624602479,"share":"https://ttm.financial/m/news/1142508463?lang=&edition=fundamental","pubTime":"2021-06-25 14:27","market":"us","language":"en","title":"China Giant Ganfeng Says Lithium May Rally to Boom-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=1142508463","media":"Bloomberg","summary":"(Bloomberg) -- Ganfeng Lithium Co., the lithium supplier that’s extending an acquisition spree, says","content":"<p>(Bloomberg) -- Ganfeng Lithium Co., the lithium supplier that’s extending an acquisition spree, says there’s a chance that a tightening market for the battery metal could push prices back toward a record high.</p>\n<p>The world’s third-largest producer of lithium chemicals, used in batteries for electric vehicles to grid-scale energy storage, is positioning to capitalize as the market extends a rebound from a more than two year slump that ended in September.</p>\n<p>“The industry is rapidly growing and we have a very upbeat forecast on lithium consumption,” Vice Chairman Wang Xiaoshen said in an interview. “I can’t rule out the possibility for lithium prices to bounce back to the 2018 level.”</p>\n<p>Lithium prices surged from 2015 to mid-2018 as rising demand from electric automakers outpaced available supply from a small network of mining and refining companies. A subsequent rush to add new sources of raw materials, chiefly from Australian mines and South American brine operations, then sent the metal tumbling.</p>\n<p>Moves by the industry to halt development of new projects amid that sell-off has meant a near-term tightening of the lithium market, and Wang said it’ll take time for the revived expansions and new operations to deliver new supply. That could see a deficit late this year or in 2022, he said.</p>\n<p>At the same time, demand for both battery-powered vehicles and storage systems for renewable energy is building quickly. “We will step up efforts on the exploration of lithium resources to meet the market needs,” Wang said.</p>\n<p>Jiangxi-based Ganfeng, which raised $628 million in a share placement this month, has made new investments recently in projects in Mexico and Mali, adding to stakes in mining and brine operations in locations including Argentina, Australia and China.</p>\n<p>Shares in Hong Kong climbed more than 3% and are up 25% this year.</p>\n<p>Accelerating sales of electric cars and government stimulus programs aimed at encouraging adoption of greener energy are adding to lithium’s positive outlook. Demand for lithium-ion batteries is expected to jump tenfold by 2030, according to BloombergNEF.</p>\n<p>“Prices for lithium chemicals will still have room to rise by the end of the year, demand for EV batteries and energy storage is still strong,” said Xiaoyi Liu, an analyst at Shanghai Metals Market.</p>\n<p>According to Morgan Stanley, high spot prices in China reflect tight supply, strong demand, and low inventory. Smaller converters are already running out of raw materials and higher prices are likely to lead to gradual mining restarts in Australia in the second half, the bank said in a note.</p>\n<p>Still, there are risks of a repeat of the sector’s 2018 tumble, according to Wang. Prices could pull-back if miners fire up supply projects too quickly, or if the pace of EV sales slips, he said in the Monday interview.</p>\n<p>While the lithium market will remain tight for the next two years, beyond that “lithium producers will need to manage supply growth in a sustainable manner to avoid another crash in prices as occurred in 2018,” BNEF analysts Kwasi Ampofo and Peng Xu said in a note this month.</p>\n<p>Over the longer-term, the recovery of metals including lithium through battery recycling will also impact the market. Ganfeng currently has recycling facilities in China capable of handling about 65,000 tons of spent batteries a year, and is considering building overseas plants, according to Wang.</p>\n<p>Until there’s a more developed electric car industry, and higher volumes of battery packs -- that typically last at least eight years in a vehicle -- it’s likely to remain a small source of supply, and may account only for about 10% to 15% of the lithium market after 2040, he said.</p>\n<p>“We have customers and carmakers making queries over the supply of recycled lithium carbonate or hydroxide from retired cells,” said Wang. “It’s just that the batteries available for recycling are still relatively little at the moment.”</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Giant Ganfeng Says Lithium May Rally to Boom-Time High</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Giant Ganfeng Says Lithium May Rally to Boom-Time High\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/china-giant-ganfeng-says-lithium-210000456.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Ganfeng Lithium Co., the lithium supplier that’s extending an acquisition spree, says there’s a chance that a tightening market for the battery metal could push prices back toward a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/china-giant-ganfeng-says-lithium-210000456.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01772":"赣锋锂业"},"source_url":"https://finance.yahoo.com/news/china-giant-ganfeng-says-lithium-210000456.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142508463","content_text":"(Bloomberg) -- Ganfeng Lithium Co., the lithium supplier that’s extending an acquisition spree, says there’s a chance that a tightening market for the battery metal could push prices back toward a record high.\nThe world’s third-largest producer of lithium chemicals, used in batteries for electric vehicles to grid-scale energy storage, is positioning to capitalize as the market extends a rebound from a more than two year slump that ended in September.\n“The industry is rapidly growing and we have a very upbeat forecast on lithium consumption,” Vice Chairman Wang Xiaoshen said in an interview. “I can’t rule out the possibility for lithium prices to bounce back to the 2018 level.”\nLithium prices surged from 2015 to mid-2018 as rising demand from electric automakers outpaced available supply from a small network of mining and refining companies. A subsequent rush to add new sources of raw materials, chiefly from Australian mines and South American brine operations, then sent the metal tumbling.\nMoves by the industry to halt development of new projects amid that sell-off has meant a near-term tightening of the lithium market, and Wang said it’ll take time for the revived expansions and new operations to deliver new supply. That could see a deficit late this year or in 2022, he said.\nAt the same time, demand for both battery-powered vehicles and storage systems for renewable energy is building quickly. “We will step up efforts on the exploration of lithium resources to meet the market needs,” Wang said.\nJiangxi-based Ganfeng, which raised $628 million in a share placement this month, has made new investments recently in projects in Mexico and Mali, adding to stakes in mining and brine operations in locations including Argentina, Australia and China.\nShares in Hong Kong climbed more than 3% and are up 25% this year.\nAccelerating sales of electric cars and government stimulus programs aimed at encouraging adoption of greener energy are adding to lithium’s positive outlook. Demand for lithium-ion batteries is expected to jump tenfold by 2030, according to BloombergNEF.\n“Prices for lithium chemicals will still have room to rise by the end of the year, demand for EV batteries and energy storage is still strong,” said Xiaoyi Liu, an analyst at Shanghai Metals Market.\nAccording to Morgan Stanley, high spot prices in China reflect tight supply, strong demand, and low inventory. Smaller converters are already running out of raw materials and higher prices are likely to lead to gradual mining restarts in Australia in the second half, the bank said in a note.\nStill, there are risks of a repeat of the sector’s 2018 tumble, according to Wang. Prices could pull-back if miners fire up supply projects too quickly, or if the pace of EV sales slips, he said in the Monday interview.\nWhile the lithium market will remain tight for the next two years, beyond that “lithium producers will need to manage supply growth in a sustainable manner to avoid another crash in prices as occurred in 2018,” BNEF analysts Kwasi Ampofo and Peng Xu said in a note this month.\nOver the longer-term, the recovery of metals including lithium through battery recycling will also impact the market. Ganfeng currently has recycling facilities in China capable of handling about 65,000 tons of spent batteries a year, and is considering building overseas plants, according to Wang.\nUntil there’s a more developed electric car industry, and higher volumes of battery packs -- that typically last at least eight years in a vehicle -- it’s likely to remain a small source of supply, and may account only for about 10% to 15% of the lithium market after 2040, he said.\n“We have customers and carmakers making queries over the supply of recycled lithium carbonate or hydroxide from retired cells,” said Wang. “It’s just that the batteries available for recycling are still relatively little at the moment.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148612802,"gmtCreate":1625971047206,"gmtModify":1703751415913,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Any security issue? ?","listText":"Any security issue? ?","text":"Any security issue? ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/148612802","repostId":"1184476863","repostType":4,"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122183719,"gmtCreate":1624604037331,"gmtModify":1703841523325,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Good stock","listText":"Good stock","text":"Good stock","images":[{"img":"https://static.tigerbbs.com/4f8385126ac4e0cf0ec5814a4a5cadee","width":"1080","height":"2110"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122183719","isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":122189388,"gmtCreate":1624603925044,"gmtModify":1703841520236,"author":{"id":"4087701495835990","authorId":"4087701495835990","name":"HoraceQ","avatar":"https://static.tigerbbs.com/44d8d7efd471b45e4018aa51d394308d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087701495835990","authorIdStr":"4087701495835990"},"themes":[],"htmlText":"Good?&nbsp;","listText":"Good?&nbsp;","text":"Good?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122189388","repostId":"1114781833","repostType":4,"repost":{"id":"1114781833","kind":"news","pubTimestamp":1624601893,"share":"https://ttm.financial/m/news/1114781833?lang=&edition=fundamental","pubTime":"2021-06-25 14:18","market":"us","language":"en","title":"Japan's Rakuten to use Cisco routing tech for 5G, IoT services","url":"https://stock-news.laohu8.com/highlight/detail?id=1114781833","media":"Reuters","summary":"STOCKHOLM (Reuters) - Rakuten Mobile said on Friday that it plans to use new routing technologies fr","content":"<p>STOCKHOLM (Reuters) - Rakuten Mobile said on Friday that it plans to use new routing technologies from network gear maker Cisco to expand its capacity to support business customers with 5G and so-called Internet of Things (IoT) services.</p>\n<p>The Japanese firm has become the first mobile operator to deploy a network based on Open Radio Access Network (RAN) technology that uses software to run network functions on the cloud, reducing the requirement for physical equipment.</p>\n<p>Rakuten, with 4 million subscribers, will use the new technology to make the entire network more automated to deploy services faster, reduce latency and lower power consumption.</p>\n<p>\"We are going big into enterprise now, in a very elegant cost-efficient manner, without having to incur cost addition,\" Chief Technology Officer Tareq Amin told analysts on a telephone call.</p>\n<p>Companies such as Dish Network, which is racing to build a 5G network in the United States by 2023, are also building networks based on Open RAN as it promises to radically cut costs.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan's Rakuten to use Cisco routing tech for 5G, IoT services</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan's Rakuten to use Cisco routing tech for 5G, IoT services\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 14:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/japans-rakuten-cisco-routing-tech-061457695.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>STOCKHOLM (Reuters) - Rakuten Mobile said on Friday that it plans to use new routing technologies from network gear maker Cisco to expand its capacity to support business customers with 5G and so-...</p>\n\n<a href=\"https://finance.yahoo.com/news/japans-rakuten-cisco-routing-tech-061457695.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CSCO":"思科"},"source_url":"https://finance.yahoo.com/news/japans-rakuten-cisco-routing-tech-061457695.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114781833","content_text":"STOCKHOLM (Reuters) - Rakuten Mobile said on Friday that it plans to use new routing technologies from network gear maker Cisco to expand its capacity to support business customers with 5G and so-called Internet of Things (IoT) services.\nThe Japanese firm has become the first mobile operator to deploy a network based on Open Radio Access Network (RAN) technology that uses software to run network functions on the cloud, reducing the requirement for physical equipment.\nRakuten, with 4 million subscribers, will use the new technology to make the entire network more automated to deploy services faster, reduce latency and lower power consumption.\n\"We are going big into enterprise now, in a very elegant cost-efficient manner, without having to incur cost addition,\" Chief Technology Officer Tareq Amin told analysts on a telephone call.\nCompanies such as Dish Network, which is racing to build a 5G network in the United States by 2023, are also building networks based on Open RAN as it promises to radically cut costs.","news_type":1},"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}